Viracta Therapeutics: Funding, Investors & Team (Sep 2026)
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
Viracta Therapeutics has raised $50.0M across 1 funding round on record, the most recent a Post-IPO Debt of $50.0M announced in Nov 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Viracta Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Viracta Therapeutics Funding Rounds
Viracta Therapeutics Founders and Leadership Team
Contact details for the Viracta Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Viracta Therapeutics Funding Compared to Other Biotechnology Startups
Viracta Therapeutics' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Viracta Therapeutics in Biotechnology and Cardiff By The Sea
Companies Similar to Viracta Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Viracta Therapeutics Funding FAQs
What does Viracta Therapeutics do?
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
How much funding has Viracta Therapeutics raised?
Viracta Therapeutics has raised $50.0M across 1 round on record. The most recent is a Post-IPO Debt of $50.0M announced in Nov 2021.
When did Viracta Therapeutics last raise funding?
Viracta Therapeutics' most recent funding round on record is a Post-IPO Debt of $50.0M, announced in Nov 2021.
Who is the CEO of Viracta Therapeutics?
Ivor Royston is listed as CEO at Viracta Therapeutics.
Where is Viracta Therapeutics headquartered?
Viracta Therapeutics is based in Cardiff By The Sea, California, United States.
How many employees does Viracta Therapeutics have?
Viracta Therapeutics is in the 11-50 employee band.
How does Viracta Therapeutics' funding compare to other Biotechnology startups?
Viracta Therapeutics' latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Viracta Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Viracta Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.